Jpmorgan Chase & CO Nautilus Biotechnology, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Nautilus Biotechnology, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 64,836 shares of NAUT stock, worth $46,033. This represents 0.0% of its overall portfolio holdings.
Number of Shares
64,836
Previous 145,937
55.57%
Holding current value
$46,033
Previous $245,000
77.55%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding NAUT
# of Institutions
73Shares Held
62.7MCall Options Held
158KPut Options Held
0-
Ah Equity Partners Bio Ii, L.L.C. Menlo Park, CA16.3MShares$11.6 Million24.08% of portfolio
-
Perceptive Advisors LLC New York, NY12.6MShares$8.94 Million0.4% of portfolio
-
Cercano Management LLC Bellevue, WA7.17MShares$5.09 Million0.16% of portfolio
-
Madrona Venture Group, LLC6.02MShares$4.27 Million34.58% of portfolio
-
Black Rock Inc. New York, NY3.83MShares$2.72 Million0.0% of portfolio
About Nautilus Biotechnology, Inc.
- Ticker NAUT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,663,000
- Market Cap $88.5M
- Description
- Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was found...